Arcutis Biotherapeutics, Inc. balance sheet ARQT

Annual Quarterly

As of Sep 30, 2026, Arcutis Biotherapeutics, Inc. had total assets of $524.4 million and total liabilities of $280.5 million. Total assets were up 41.4% from a year earlier. Stockholders' equity was $244.0 million. It held $259.5 million in cash and investments against $114.6 million of total debt, net cash of $144.8 million. The current ratio, current assets divided by current liabilities, was 2.92.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Assets
Cash
33
-29.2%
43
-39.9%
71
-19.3%
88
+64.8%
54
-44.4%
96
+48.2%
65
Short-term investments
226
+57.1%
178
+13.7%
157
-14.6%
183
-48.5%
356
+22.5%
291
+32.5%
219
Cash and investments
259
+35.8%
221
-3.1%
228
-16.1%
272
-33.6%
410
+5.8%
387
+36.1%
284
Receivables
171
+48.8%
146
+100.1%
73
+183.1%
26
+205.1%
8
—
—
Inventory
46
+103.7%
23
+55.8%
15
+10.6%
13
+74.8%
8
—
—
Total current assets
504
+44.2%
411
+22.5%
336
+1.6%
330
-24.5%
437
+8.6%
403
+37.5%
293
Property and equipment, net
1
-34.5%
1
+0.2%
1
-32.4%
2
-18.2%
2
-16.8%
2
+12.2%
2
Total assets
524
+41.4%
433
+24.1%
349
+2.2%
341
-24.0%
449
+10.1%
408
+36.8%
298
Liabilities and equity
Accounts payable
8
+44.0%
13
-11.9%
14
+18.6%
12
+35.9%
9
+20.0%
7
+3.0%
7
Total current liabilities
172
+72.8%
130
+60.3%
81
+73.6%
47
+23.4%
38
+13.4%
33
+47.4%
23
Total liabilities
280
+31.7%
243
+27.3%
191
-24.3%
253
+5.4%
240
+117.0%
110
+299.6%
28
Stockholders' equity
244
+54.3%
189
+20.3%
158
+77.7%
89
-57.7%
210
-29.6%
298
+10.0%
271
Debt
Debt due within a year
7
+595.0%
1
—
—
—
—
—
Long-term debt
102
-4.7%
108
+0.7%
107
-46.9%
202
+2.0%
198
+173.4%
72
—
Lease liabilities
5
-1.0%
6
+64.4%
3
-17.9%
4
-13.8%
5
-8.3%
5
+4.9%
5
Total debt
115
+0.7%
115
+3.6%
111
-46.3%
206
+1.7%
203
+161.2%
78
+1462.4%
5
Net cash
145
+87.4%
106
-9.3%
117
+78.0%
66
-68.2%
207
-33.1%
310
+10.7%
279
Ratios
Current ratio
2.92x
3.17x
4.15x
7.08x
11.57x
12.09x
12.96x
Debt to equity
0.47x
0.60x
0.70x
2.32x
0.97x
0.26x
0.02x
Return on equity
12.26%
-8.52%
-88.89%
-295.65%
-148.61%
-69.32%
-50.14%
Return on assets
5.70%
-3.73%
-40.14%
-76.79%
-69.32%
-50.56%
-45.49%
Book value per share
1.94
1.54
1.34
0.92
3.43
5.92
6.24
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ARQT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Westlake Village, CA
SEC filer status
Large accelerated filer
SEC CIK
1787306
Former names
Arcutis, Inc. (until Sep 9, 2019)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.